Literature DB >> 22726283

Seborrheic dermatitis: an update.

Zrinka Bukvić Mokos1, Martina Kralj, Aleksandra Basta-Juzbašić, Ines Lakoš Jukić.   

Abstract

Seborrheic dermatitis is a chronic relapsing inflammatory skin disorder clinically characterized by scaling and poorly defined erythematous patches. The prevalence of adult seborrheic dermatitis is estimated at 5%. Although the exact cause of seborrheic dermatitis has yet to be understood, Malassezia yeasts, hormones (androgens), sebum levels and immune response are known to play important roles in its development. Additional factors including drugs, winter temperatures and stress may exacerbate seborrheic dermatitis. A variety of treatment modalities are available, including antifungal agents, topical low-potency steroids and calcineurin inhibitors (immunomodulators). This review summarizes current knowledge on the etiopathogenesis and therapy of adult seborrheic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22726283

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  13 in total

Review 1.  Bitemporal Scalp Hair Loss: Differential Diagnosis of Nonscarring and Scarring Conditions.

Authors:  Brianna De Souza; Andrea Tovar-Garza; Laura N Uwakwe; Amy McMichael
Journal:  J Clin Aesthet Dermatol       Date:  2021-02-01

2.  Evaluation of a Topical Anti-inflammatory/Antifungal Combination Cream in Mild-to-moderate Facial Seborrheic Dermatitis: An Intra-subject Controlled Trial Examining Treated vs. Untreated Skin Utilizing Clinical Features and Erythema-directed Digital Photography.

Authors:  Federica Dall'Oglio; Aurora Tedeschi; Vincenzo Guardabasso; Giuseppe Micali
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

3.  Noncorticosteroid Combination Shampoo versus 1% Ketoconazole Shampoo for the Management of Mild-to-Moderate Seborrheic Dermatitis of the Scalp: Results from a Randomized, Investigator-Single-Blind Trial Using Clinical and Trichoscopic Evaluation.

Authors:  Federica Dall'Oglio; Francesco Lacarrubba; Anna Elisa Verzì; Giuseppe Micali
Journal:  Skin Appendage Disord       Date:  2015-10-17

4.  Malassezia intra-specific diversity and potentially new species in the skin microbiota from Brazilian healthy subjects and seborrheic dermatitis patients.

Authors:  Renan Cardoso Soares; Marcelo Bergamin Zani; Ana Carolina Belini Bazán Arruda; Lucia Helena Fávaro de Arruda; Luciana Campos Paulino
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

5.  Profile of patients admitted to a triage dermatology clinic at a tertiary hospital in São Paulo, Brazil.

Authors:  Fernanda Bertanha; Erica Judite Pimentel Nelumba; Alyne Korukian Freiberg; Luciana Paula Samorano; Cyro Festa
Journal:  An Bras Dermatol       Date:  2016 May-Jun       Impact factor: 1.896

6.  Clinical and instrumental evaluation of a new topical non-corticosteroid antifungal/anti-inflammatory/antiseborrheic combination cream for the treatment of mild-to-moderate facial seborrheic dermatitis.

Authors:  Federica Dall'Oglio; Francesco Lacarrubba; Maria Luca; Simona Boscaglia; Corinne Granger; Giuseppe Micali
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-01-24

Review 7.  Topical Non-Pharmacological Treatment for Facial Seborrheic Dermatitis.

Authors:  Jaime Piquero-Casals; Doris Hexsel; Juan Francisco Mir-Bonafé; Eduardo Rozas-Muñoz
Journal:  Dermatol Ther (Heidelb)       Date:  2019-08-08

8.  Second-to-fourth digit ratio and seborrheic dermatitis in males: a cross-sectional study.

Authors:  Zeynep Gizem Kaya İslamoğlu
Journal:  An Bras Dermatol       Date:  2019-07-29       Impact factor: 1.896

9.  Seborrheic Dermatitis and Dandruff: A Comprehensive Review.

Authors:  Luis J Borda; Tongyu C Wikramanayake
Journal:  J Clin Investig Dermatol       Date:  2015-12-15

Review 10.  Short antimicrobial peptides as cosmetic ingredients to deter dermatological pathogens.

Authors:  Mohammad Rahnamaeian; Andreas Vilcinskas
Journal:  Appl Microbiol Biotechnol       Date:  2015-08-26       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.